To assess the prevalence of possible sarcopenia and sarcopenic obesity phenotypes and investigate their association with self-reported diabetes among community-dwelling individuals aged 45 or above.
Methods
Utilizing data from 62,899 individuals in LASI wave-1 (2017-18), the assessment of possible sarcopenia was done on two critical parameters: muscle (handgrip) strength and physical performance (gait speed), following the 2019 guidelines from the Asian working group on sarcopenia (AWGS). BMI, WC, WHR, and WHtR defined sarcopenic obesity phenotypes. Binary logistic regression analysis explored the association of possible sarcopenia and sarcopenic obesity phenotypes with self-reported diabetes.
Results
The prevalence of possible sarcopenia and sarcopenic obesity defined by BMI was found to be 44.4 % and 10.6 %, respectively. Individuals with possible sarcopenia exhibited a 1.18 times higher likelihood of developing self-reported diabetes (p < 0.001), while those with sarcopenic obesity by BMI had significantly elevated odds (1.94, 95 % CI 1.81–2, p < 0.001) for self-reported diabetes.
Conclusions
Sarcopenia and sarcopenic obesity phenotypes may increase the risk of developing diabetes as we age. Therefore, it is imperative to formulate targeted preventive and therapeutic strategies to combat sarcopenia and diabetes among the aging population.
{"title":"Possible sarcopenia, sarcopenic obesity phenotypes and their association with diabetes: Evidence from LASI wave-1 (2017-18)","authors":"Inderdeep Kaur , Shromona Das , Shivangi Chandel , Shivani Chandel","doi":"10.1016/j.dsx.2025.103185","DOIUrl":"10.1016/j.dsx.2025.103185","url":null,"abstract":"<div><h3>Aims</h3><div>To assess the prevalence of possible sarcopenia and sarcopenic obesity phenotypes and investigate their association with self-reported diabetes among community-dwelling individuals aged 45 or above.</div></div><div><h3>Methods</h3><div>Utilizing data from 62,899 individuals in LASI wave-1 (2017-18), the assessment of possible sarcopenia was done on two critical parameters: muscle (handgrip) strength and physical performance (gait speed), following the 2019 guidelines from the Asian working group on sarcopenia (AWGS). BMI, WC, WHR, and WHtR defined sarcopenic obesity phenotypes. Binary logistic regression analysis explored the association of possible sarcopenia and sarcopenic obesity phenotypes with self-reported diabetes.</div></div><div><h3>Results</h3><div>The prevalence of possible sarcopenia and sarcopenic obesity defined by BMI was found to be 44.4 % and 10.6 %, respectively. Individuals with possible sarcopenia exhibited a 1.18 times higher likelihood of developing self-reported diabetes (p < 0.001), while those with sarcopenic obesity by BMI had significantly elevated odds (1.94, 95 % CI 1.81–2, p < 0.001) for self-reported diabetes.</div></div><div><h3>Conclusions</h3><div>Sarcopenia and sarcopenic obesity phenotypes may increase the risk of developing diabetes as we age. Therefore, it is imperative to formulate targeted preventive and therapeutic strategies to combat sarcopenia and diabetes among the aging population.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 2","pages":"Article 103185"},"PeriodicalIF":4.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143014258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-01DOI: 10.1016/j.dsx.2025.103201
Volker H. Schmitt , Lukas Hobohm , Omar Hahad , Visvakanth Sivanathan , Frank P. Schmidt , Thomas Münzel , Philipp Lurz , Tommaso Gori , Karsten Keller
Introduction
Type 1 diabetes mellitus (T1D) is associated with an increased cardiovascular risk. We aimed to investigate the influence of T1D on myocardial infarction (MI) patients’ mortality.
Materials and methods
The German nationwide inpatient sample 2005–2016 was used for statistical analysis. Hospitalized MI patients were stratified for T1D and impact of T1D on in-hospital outcomes was investigated.
Results
In total, 3,307,703 hospitalizations of MI patients (37.6 % females, 56.8 % aged ≥70 years) were counted in Germany 2005–2016 and included in this analysis. In 18,625 (0.6 %) of the cases additionally T1D was coded. Overall, 410,737 (12.4 %) in-hospital deaths occurred within the investigation period. MI patients with T1D were younger (64.0 [IQR 52.0–75.0] vs. 73.0 [62.0–81.0] years, P < 0.001), more often female (38.7 % vs. 37.6 %, P < 0.001) and obese (13.2 % vs. 9.3 %, P < 0.001). Comorbidities like peripheral arterial (14.2 % vs. 6.4 %, P < 0.001) and kidney disease (38.5 % vs. 27.2 %, P < 0.001) were more prevalent in MI patients with T1D. T1D was an independent risk factor for in-hospital death (OR 1.23 [95%CI 1.18–1.29], P < 0.001), recurrent MI (OR 1.56 [95%CI 1.35–1.80], P < 0.001), and stroke (OR 1.75 [95%CI 1.63–1.88], P < 0.001). While percutaneous coronary intervention (PCI, 37.8 % vs. 42.0 %, P < 0.001) was less often, coronary artery bypass grafting (CABG, 7.4 % vs. 4.6 %, P < 0.001) was more often performed in MI patients with T1D, confirmed by regression analysis (PCI: OR 0.66 [95%CI 0.64–0.68], P < 0.001; CABG: OR 1.54 [95%CI 1.45–1.63], P < 0.001).
Conclusions
T1D represents an important and independent risk factor for mortality in MI patients. The results emphasize the high vulnerability of T1D patients who suffer from MI.
{"title":"Impact of type 1 diabetes mellitus on mortality rate and outcome of hospitalized patients with myocardial infarction","authors":"Volker H. Schmitt , Lukas Hobohm , Omar Hahad , Visvakanth Sivanathan , Frank P. Schmidt , Thomas Münzel , Philipp Lurz , Tommaso Gori , Karsten Keller","doi":"10.1016/j.dsx.2025.103201","DOIUrl":"10.1016/j.dsx.2025.103201","url":null,"abstract":"<div><h3>Introduction</h3><div>Type 1 diabetes mellitus (T1D) is associated with an increased cardiovascular risk. We aimed to investigate the influence of T1D on myocardial infarction (MI) patients’ mortality.</div></div><div><h3>Materials and methods</h3><div>The German nationwide inpatient sample 2005–2016 was used for statistical analysis. Hospitalized MI patients were stratified for T1D and impact of T1D on in-hospital outcomes was investigated.</div></div><div><h3>Results</h3><div>In total, 3,307,703 hospitalizations of MI patients (37.6 % females, 56.8 % aged ≥70 years) were counted in Germany 2005–2016 and included in this analysis. In 18,625 (0.6 %) of the cases additionally T1D was coded. Overall, 410,737 (12.4 %) in-hospital deaths occurred within the investigation period. MI patients with T1D were younger (64.0 [IQR 52.0–75.0] vs. 73.0 [62.0–81.0] years, P < 0.001), more often female (38.7 % vs. 37.6 %, P < 0.001) and obese (13.2 % vs. 9.3 %, P < 0.001). Comorbidities like peripheral arterial (14.2 % vs. 6.4 %, P < 0.001) and kidney disease (38.5 % vs. 27.2 %, P < 0.001) were more prevalent in MI patients with T1D. T1D was an independent risk factor for in-hospital death (OR 1.23 [95%CI 1.18–1.29], P < 0.001), recurrent MI (OR 1.56 [95%CI 1.35–1.80], P < 0.001), and stroke (OR 1.75 [95%CI 1.63–1.88], P < 0.001). While percutaneous coronary intervention (PCI, 37.8 % vs. 42.0 %, P < 0.001) was less often, coronary artery bypass grafting (CABG, 7.4 % vs. 4.6 %, P < 0.001) was more often performed in MI patients with T1D, confirmed by regression analysis (PCI: OR 0.66 [95%CI 0.64–0.68], P < 0.001; CABG: OR 1.54 [95%CI 1.45–1.63], P < 0.001).</div></div><div><h3>Conclusions</h3><div>T1D represents an important and independent risk factor for mortality in MI patients. The results emphasize the high vulnerability of T1D patients who suffer from MI.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 2","pages":"Article 103201"},"PeriodicalIF":4.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143081540","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-01DOI: 10.1016/j.dsx.2025.103187
Shaghayegh Khanmohammadi , Mahdi Masrour , Parisa Fallahtafti , Amirhossein Habibzadeh , Art Schuermans , Mohammad Shafi Kuchay
Background and aim
Frailty is frequently observed in end-stage liver disease of various etiologies, but its role in nonalcoholic fatty liver disease (NAFLD) remains incompletely understood. We aimed to conduct a systematic review and meta-analysis to assess the association and prevalence of frailty in NAFLD.
Methods
A systematic review of PubMed/MEDLINE, EMBASE, Web of Science, and Scopus was performed. The random-effects model was used to estimate the pooled prevalence of frailty. Meta-analyzed odds ratios (OR) were calculated to examine the association between frailty and NAFLD.
Results
Among the initial 430 articles identified, 18 studies were included. Three studies involving 3673 participants had a pooled OR of 2.03 (95% CI: 1.51–2.72; I^2 = 1.1%; p < 0.0001) for the association between frailty and NAFLD. The pooled prevalence of frailty in individuals with NAFLD was 23% (95% CI: 13%–38%; I^2 = 93.5%) using the liver frailty index (LFI) and 8% (95% CI: 3%–21%; I^2 = 98.1%) using the Fried frailty index (FFI). NAFLD patients’ mean grip strength and balance time were 26.4 kg (95% CI: 23.0–29.8) and 23s (95% CI: 10–35), respectively. Among studies that also included individuals with liver cirrhosis, grip strength was lower in those with cirrhosis vs. the broader population of those with NAFLD.
Conclusions
Our study suggests that frailty is highly prevalent in individuals with NAFLD, with a significantly higher prevalence compared to those without NAFLD. Individuals with NAFLD have more than two-fold increased odds of frailty. Assessing frailty in NAFLD patients enables targeted management to improve outcomes.
背景和目的：虚弱在各种病因的终末期肝病中经常观察到，但其在非酒精性脂肪性肝病（NAFLD）中的作用仍不完全清楚。我们的目的是进行一项系统回顾和荟萃分析，以评估NAFLD中虚弱的相关性和患病率。方法：系统回顾PubMed/MEDLINE、EMBASE、Web of Science和Scopus数据库。随机效应模型用于估计虚弱的总患病率。计算meta分析的优势比（OR）来检验虚弱和NAFLD之间的关系。结果：在最初确定的430篇文章中，纳入了18项研究。三项研究共涉及3673名受试者，合并OR为2.03 (95% CI: 1.51-2.72；i ^2 = 1.1%；结论：我们的研究表明，虚弱在NAFLD患者中非常普遍，其患病率明显高于非NAFLD患者。患有NAFLD的人身体虚弱的几率增加了两倍多。评估NAFLD患者的虚弱可以使有针对性的管理改善预后。
{"title":"The relationship between nonalcoholic fatty liver disease and frailty: A systematic review and meta-analysis","authors":"Shaghayegh Khanmohammadi , Mahdi Masrour , Parisa Fallahtafti , Amirhossein Habibzadeh , Art Schuermans , Mohammad Shafi Kuchay","doi":"10.1016/j.dsx.2025.103187","DOIUrl":"10.1016/j.dsx.2025.103187","url":null,"abstract":"<div><h3>Background and aim</h3><div>Frailty is frequently observed in end-stage liver disease of various etiologies, but its role in nonalcoholic fatty liver disease (NAFLD) remains incompletely understood. We aimed to conduct a systematic review and meta-analysis to assess the association and prevalence of frailty in NAFLD.</div></div><div><h3>Methods</h3><div>A systematic review of PubMed/MEDLINE, EMBASE, Web of Science, and Scopus was performed. The random-effects model was used to estimate the pooled prevalence of frailty. Meta-analyzed odds ratios (OR) were calculated to examine the association between frailty and NAFLD.</div></div><div><h3>Results</h3><div>Among the initial 430 articles identified, 18 studies were included. Three studies involving 3673 participants had a pooled OR of 2.03 (95% CI: 1.51–2.72; I^2 = 1.1%; <em>p</em> < 0.0001) for the association between frailty and NAFLD. The pooled prevalence of frailty in individuals with NAFLD was 23% (95% CI: 13%–38%; I^2 = 93.5%) using the liver frailty index (LFI) and 8% (95% CI: 3%–21%; I^2 = 98.1%) using the Fried frailty index (FFI). NAFLD patients’ mean grip strength and balance time were 26.4 kg (95% CI: 23.0–29.8) and 23s (95% CI: 10–35), respectively. Among studies that also included individuals with liver cirrhosis, grip strength was lower in those with cirrhosis vs. the broader population of those with NAFLD.</div></div><div><h3>Conclusions</h3><div>Our study suggests that frailty is highly prevalent in individuals with NAFLD, with a significantly higher prevalence compared to those without NAFLD. Individuals with NAFLD have more than two-fold increased odds of frailty. Assessing frailty in NAFLD patients enables targeted management to improve outcomes.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 2","pages":"Article 103187"},"PeriodicalIF":4.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142972842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-01DOI: 10.1016/j.dsx.2025.103190
Hao-Han Rao , Feng Guo , Jie Tian
{"title":"Letter to the Editor regarding “Global research trends and hotspots in gestational diabetes and long-term cardiovascular health: A bibliometric analysis.”","authors":"Hao-Han Rao , Feng Guo , Jie Tian","doi":"10.1016/j.dsx.2025.103190","DOIUrl":"10.1016/j.dsx.2025.103190","url":null,"abstract":"","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 2","pages":"Article 103190"},"PeriodicalIF":4.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143060761","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-01DOI: 10.1016/j.dsx.2025.103200
Takahiro Omoto , Hyo Kyozuka , Tsuyoshi Murata , Toma Fukuda , Hirotaka Isogami , Chihiro Okoshi , Shun Yasuda , Akiko Yamaguchi , Akiko Sato , Yuka Ogata , Yuichi Nagasaka , Mitsuaki Hosoya , Seiji Yasumura , Koichi Hashimoto , Hidekazu Nishigori , Keiya Fujimori , the Japan Environment and Children's Study Group
Aims
To investigate the relationship between preconception protein intake and the risk of gestational diabetes mellitus (GDM).
Methods
We analyzed data from the Japan Environment and Children's Study, focusing on 80,346 participants (mean age 31.3 ± 4.9 years; mean body mass index 21.2 ± 3.2 kg/m2) who delivered between 2011 and 2014. These participants had no history of diabetes mellitus, no previous diagnosis of GDM, and did not use steroids during pregnancy. Participants were categorized into five groups based on preconception protein energy ratio quintiles (Q1 and Q5 represent the lowest and highest intake, respectively). Continuous variables were compared using one-way analysis of variance or the Kruskal–Wallis test, and categorical variables using chi-square tests. Primary outcomes were GDM, early-diagnosed GDM (Ed-GDM, diagnosed at <24 weeks), and late-diagnosed GDM (Ld-GDM, diagnosed at >24 weeks). Adjusted odds ratios (aORs) and 95 % confidence intervals (CIs) were calculated using logistic regression analysis with the middle quintile (Q3) as the reference.
Results
Multiple logistic regression analysis revealed that using the Q3 group as the reference, the Q5 group had a higher risk of Ed-GDM (aOR 1.48, 95 % CI 1.06–2.07), whereas the Q1 group had a lower risk of Ed-GDM (aOR 0.69, 95 % CI 0.48–0.996). However, no significant differences were observed in the risk of GDM and Ld-GDM.
Conclusions
Higher preconception protein intake was associated with increased Ed-GDM risk. Further research is needed to refine dietary recommendations for preconception protein intake.
{"title":"Relationship between preconception protein intake and gestational diabetes mellitus: The Japan Environment and Children's Study","authors":"Takahiro Omoto , Hyo Kyozuka , Tsuyoshi Murata , Toma Fukuda , Hirotaka Isogami , Chihiro Okoshi , Shun Yasuda , Akiko Yamaguchi , Akiko Sato , Yuka Ogata , Yuichi Nagasaka , Mitsuaki Hosoya , Seiji Yasumura , Koichi Hashimoto , Hidekazu Nishigori , Keiya Fujimori , the Japan Environment and Children's Study Group","doi":"10.1016/j.dsx.2025.103200","DOIUrl":"10.1016/j.dsx.2025.103200","url":null,"abstract":"<div><h3>Aims</h3><div>To investigate the relationship between preconception protein intake and the risk of gestational diabetes mellitus (GDM).</div></div><div><h3>Methods</h3><div>We analyzed data from the Japan Environment and Children's Study, focusing on 80,346 participants (mean age 31.3 ± 4.9 years; mean body mass index 21.2 ± 3.2 kg/m<sup>2</sup>) who delivered between 2011 and 2014. These participants had no history of diabetes mellitus, no previous diagnosis of GDM, and did not use steroids during pregnancy. Participants were categorized into five groups based on preconception protein energy ratio quintiles (Q1 and Q5 represent the lowest and highest intake, respectively). Continuous variables were compared using one-way analysis of variance or the Kruskal–Wallis test, and categorical variables using chi-square tests. Primary outcomes were GDM, early-diagnosed GDM (Ed-GDM, diagnosed at <24 weeks), and late-diagnosed GDM (Ld-GDM, diagnosed at >24 weeks). Adjusted odds ratios (aORs) and 95 % confidence intervals (CIs) were calculated using logistic regression analysis with the middle quintile (Q3) as the reference.</div></div><div><h3>Results</h3><div>Multiple logistic regression analysis revealed that using the Q3 group as the reference, the Q5 group had a higher risk of Ed-GDM (aOR 1.48, 95 % CI 1.06–2.07), whereas the Q1 group had a lower risk of Ed-GDM (aOR 0.69, 95 % CI 0.48–0.996). However, no significant differences were observed in the risk of GDM and Ld-GDM.</div></div><div><h3>Conclusions</h3><div>Higher preconception protein intake was associated with increased Ed-GDM risk. Further research is needed to refine dietary recommendations for preconception protein intake.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 2","pages":"Article 103200"},"PeriodicalIF":4.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143228576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Obesity is a global health crisis linked to numerous chronic diseases. The gut microbiome plays a crucial role in human metabolism, and emerging evidence suggests that modulating the microbiome may offer novel therapeutic avenues for obesity management.
Objective
This systematic review aimed to assess the efficacy and safety of microbiome-targeted interventions, including probiotics, prebiotics, synbiotics, and fecal microbiota transplantation, in improving body composition, metabolic parameters, and inflammatory markers in overweight and obese adults.
Methods
A comprehensive search of PubMed, Scopus, and ScienceDirect was conducted to identify relevant studies published between 2005 and 2023. Included studies were assessed for methodological quality and risk of bias using the Cochrane Collaboration tool.
Results
Body composition: Most studies demonstrated significant reductions in body weight, Body mass index, and body fat percentage.
Metabolic parameters
Improvements were observed in lipid profiles (reduced cholesterol, triglycerides) and glucose metabolism (improved insulin sensitivity).
Inflammatory markers
Significant reductions were observed in inflammatory markers such as Interleukins (IL-6, IL-8) and C-reactive protein.
Microbial composition
Interventions generally led to shifts in microbial composition, with increases in beneficial bacteria such as Bifidobacterium and Lactobacillus.
Adverse events
Adverse events were generally minimal and limited.
Conclusion
This review provides strong evidence that microbiome-targeted interventions can effectively improve body composition, metabolic parameters, and inflammatory markers in individuals with obesity. Further research is needed to optimize intervention strategies, identify specific microbial targets, and translate these findings into effective clinical applications.
{"title":"Efficacy of microbiome-targeted interventions in obesity management- A comprehensive systematic review","authors":"Dhivya Dhanasekaran , Manojkumar Venkatesan , Sarvesh Sabarathinam","doi":"10.1016/j.dsx.2025.103208","DOIUrl":"10.1016/j.dsx.2025.103208","url":null,"abstract":"<div><h3>Background</h3><div>Obesity is a global health crisis linked to numerous chronic diseases. The gut microbiome plays a crucial role in human metabolism, and emerging evidence suggests that modulating the microbiome may offer novel therapeutic avenues for obesity management.</div></div><div><h3>Objective</h3><div>This systematic review aimed to assess the efficacy and safety of microbiome-targeted interventions, including probiotics, prebiotics, synbiotics, and fecal microbiota transplantation, in improving body composition, metabolic parameters, and inflammatory markers in overweight and obese adults.</div></div><div><h3>Methods</h3><div>A comprehensive search of PubMed, Scopus, and ScienceDirect was conducted to identify relevant studies published between 2005 and 2023. Included studies were assessed for methodological quality and risk of bias using the Cochrane Collaboration tool.</div></div><div><h3>Results</h3><div><strong>Body composition</strong>: Most studies demonstrated significant reductions in body weight, Body mass index, and body fat percentage.</div></div><div><h3>Metabolic parameters</h3><div>Improvements were observed in lipid profiles (reduced cholesterol, triglycerides) and glucose metabolism (improved insulin sensitivity).</div></div><div><h3>Inflammatory markers</h3><div>Significant reductions were observed in inflammatory markers such as Interleukins (IL-6, IL-8) and C-reactive protein.</div></div><div><h3>Microbial composition</h3><div>Interventions generally led to shifts in microbial composition, with increases in beneficial bacteria such as Bifidobacterium and Lactobacillus.</div></div><div><h3>Adverse events</h3><div>Adverse events were generally minimal and limited.</div></div><div><h3>Conclusion</h3><div>This review provides strong evidence that microbiome-targeted interventions can effectively improve body composition, metabolic parameters, and inflammatory markers in individuals with obesity. Further research is needed to optimize intervention strategies, identify specific microbial targets, and translate these findings into effective clinical applications.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 2","pages":"Article 103208"},"PeriodicalIF":4.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143474769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-01DOI: 10.1016/j.dsx.2025.103191
Yanxi Jia , Qing Hu , Hua Liao , Hongyan Liu , Zhaomin Zeng , Haiyan Yu
{"title":"Response to the Letter to the Editor regarding “Global research trends and hotspots in gestational diabetes and long-term cardiovascular health: A bibliometric analysis.”","authors":"Yanxi Jia , Qing Hu , Hua Liao , Hongyan Liu , Zhaomin Zeng , Haiyan Yu","doi":"10.1016/j.dsx.2025.103191","DOIUrl":"10.1016/j.dsx.2025.103191","url":null,"abstract":"","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 2","pages":"Article 103191"},"PeriodicalIF":4.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143030109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-01DOI: 10.1016/j.dsx.2025.103206
Choon Ming Ng, Wing Loong Cheong, Chun Wie Chong, Siew Li Teoh, Wuan Shuen Yap, Shaun Wen Huey Lee
{"title":"Digital technologies for prediabetes: A systematic review and meta-analysis","authors":"Choon Ming Ng, Wing Loong Cheong, Chun Wie Chong, Siew Li Teoh, Wuan Shuen Yap, Shaun Wen Huey Lee","doi":"10.1016/j.dsx.2025.103206","DOIUrl":"10.1016/j.dsx.2025.103206","url":null,"abstract":"","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 2","pages":"Article 103206"},"PeriodicalIF":4.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143403222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-01DOI: 10.1016/j.dsx.2025.103203
Huiwon Kang , Un Jae Lee , Bum Yong Park , Minju Kim , Mihi Yang
Aims
To investigate the effects of magnesium (Mg) from deep ocean sources, we conducted a randomized clinical trial involving adults with hypertension, diabetes, or hyperlipidemia.
Methods
Subjects consumed either Mg-enriched water (MEW) or a placebo (80 or 6 mg of Mg per 2 L/day, respectively) for 4 weeks. We examined the detoxifying effects of MEW on environmental toxicants, including polycyclic aromatic hydrocarbons (PAHs) and oxidative stress, and its impact on gut microbiome composition (N = 30; 49.26 ± 9.55 yrs).
Results
Most subjects consumed less Mg than the RDA, enabling their participation in the trial. Despite limitations in serum Mg measurement to assess Mg intake, MEW intake led to improvements in body mass index (BMI), insulin levels, triglycerides, glucose-BMI, and fatigue. Regardless of Mg content, water consumption reduced urinary levels of 1-hydroxypyrene, a major PAH metabolite, and malondialdehyde, an oxidative stress biomarker. Moreover, the MEW group exhibited greater diversity in gut microbiome composition than the placebo group. Notably, MEW kept the abundance of Clostridium, Dorea, or Desulfovibrio, indicating a balanced Mg intake.
Conclusion
MEW (80 mg of Mg/day) appears safe for RDA and effective for preventing CVD or T2DM, as evidenced by gut microbiome and biomarker outcomes.
{"title":"Effects of deep ocean-derived magnesium-enhanced water on metabolic diseases with microbiome changes","authors":"Huiwon Kang , Un Jae Lee , Bum Yong Park , Minju Kim , Mihi Yang","doi":"10.1016/j.dsx.2025.103203","DOIUrl":"10.1016/j.dsx.2025.103203","url":null,"abstract":"<div><h3>Aims</h3><div>To investigate the effects of magnesium (Mg) from deep ocean sources, we conducted a randomized clinical trial involving adults with hypertension, diabetes, or hyperlipidemia.</div></div><div><h3>Methods</h3><div>Subjects consumed either Mg-enriched water (MEW) or a placebo (80 or 6 mg of Mg per 2 L/day, respectively) for 4 weeks. We examined the detoxifying effects of MEW on environmental toxicants, including polycyclic aromatic hydrocarbons (PAHs) and oxidative stress, and its impact on gut microbiome composition (N = 30; 49.26 ± 9.55 yrs).</div></div><div><h3>Results</h3><div>Most subjects consumed less Mg than the RDA, enabling their participation in the trial. Despite limitations in serum Mg measurement to assess Mg intake, MEW intake led to improvements in body mass index (BMI), insulin levels, triglycerides, glucose-BMI, and fatigue. Regardless of Mg content, water consumption reduced urinary levels of 1-hydroxypyrene, a major PAH metabolite, and malondialdehyde, an oxidative stress biomarker. Moreover, the MEW group exhibited greater diversity in gut microbiome composition than the placebo group. Notably, MEW kept the abundance of <em>Clostridium</em>, <em>Dorea</em>, or <em>Desulfovibrio</em>, indicating a balanced Mg intake.</div></div><div><h3>Conclusion</h3><div>MEW (80 mg of Mg/day) appears safe for RDA and effective for preventing CVD or T2DM, as evidenced by gut microbiome and biomarker outcomes.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 2","pages":"Article 103203"},"PeriodicalIF":4.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143396057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-01DOI: 10.1016/j.dsx.2025.103202
Mallika Prem Senthil , Eilish Devlin , Abolfazl Hassani, Eugene Lee, Royston Yi Sheng An, Steven Oh, Joshua Barclay, Muhammad Husnain, Jose J. Estevez, Ranjay Chakraborty
Aims
This review investigates literature on systemic melatonin levels and circadian timing in diabetic retinopathy (DR), examining their associations with DR.
Methods
Our search was conducted in March 14, 2024, and included the databases Medline, Web of Science, Scopus, ProQuest Health, Latin American and Caribbean Health Sciences Literature (LILACS), Cochrane, International Standard Randomised Controlled Trial Number (ISRCTN) registry, and International Clinical Trials Registry Platform (ICTRP).
Results
Our review analysed twelve articles measuring melatonin concentration in saliva, blood serum, urine, or aqueous humour. Studies measuring melatonin levels in saliva found no significant differences in the average nocturnal or daytime melatonin levels between type 2 diabetes (T2D) patients with and without DR. The studies comparing serum melatonin levels in patients with different stages of DR and controls showed inconsistent results. Only two studies measured the endogenous onset of melatonin secretion, known as dim light melatonin onset (DLMO), a highly accurate biomarker for circadian regulation. These studies showed that only 33% and 57% of patients with DR had detectable DLMO in saliva and serum, respectively. All studies evaluating overnight melatonin production using urinary aMT6s (urinary 6-sulfaoxymelatonin) levels found that DR was associated with lower nocturnal melatonin production.
Conclusions
Our review results showed evidence of reduced nocturnal melatoin production in DR with no significant changes in melatonin circadian timing.
{"title":"The role of melatonin and circadian rhythms in the pathogenesis of diabetic retinopathy: A systematic review","authors":"Mallika Prem Senthil , Eilish Devlin , Abolfazl Hassani, Eugene Lee, Royston Yi Sheng An, Steven Oh, Joshua Barclay, Muhammad Husnain, Jose J. Estevez, Ranjay Chakraborty","doi":"10.1016/j.dsx.2025.103202","DOIUrl":"10.1016/j.dsx.2025.103202","url":null,"abstract":"<div><h3>Aims</h3><div>This review investigates literature on systemic melatonin levels and circadian timing in diabetic retinopathy (DR), examining their associations with DR.</div></div><div><h3>Methods</h3><div>Our search was conducted in March 14, 2024, and included the databases Medline, Web of Science, Scopus, ProQuest Health, Latin American and Caribbean Health Sciences Literature (LILACS), Cochrane, International Standard Randomised Controlled Trial Number (ISRCTN) registry, and International Clinical Trials Registry Platform (ICTRP).</div></div><div><h3>Results</h3><div>Our review analysed twelve articles measuring melatonin concentration in saliva, blood serum, urine, or aqueous humour. Studies measuring melatonin levels in saliva found no significant differences in the average nocturnal or daytime melatonin levels between type 2 diabetes (T2D) patients with and without DR. The studies comparing serum melatonin levels in patients with different stages of DR and controls showed inconsistent results. Only two studies measured the endogenous onset of melatonin secretion, known as dim light melatonin onset (DLMO), a highly accurate biomarker for circadian regulation. These studies showed that only 33% and 57% of patients with DR had detectable DLMO in saliva and serum, respectively. All studies evaluating overnight melatonin production using urinary aMT6s (urinary 6-sulfaoxymelatonin) levels found that DR was associated with lower nocturnal melatonin production.</div></div><div><h3>Conclusions</h3><div>Our review results showed evidence of reduced nocturnal melatoin production in DR with no significant changes in melatonin circadian timing.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 2","pages":"Article 103202"},"PeriodicalIF":4.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143376541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号